AGTC to Present at Upcoming Investor Conferences

Alachua, Florida, UNITED STATES

GAINESVILLE, Fla., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that company management will participate in upcoming investor conferences.

  • Piper Jaffray Heartland Summit on Thursday, August 7th, 2014 in Minneapolis. Sue Washer, President and CEO will participate in a panel discussing advances in gene therapy.
  • Wedbush Securities Life Sciences Management Access Conference on Wednesday, August 13th, 2014 at 1:20pm ET in New York. Ms. Washer will provide a corporate overview discussing the company's lead programs in ophthalmology, including X-linked Retinoschisis (XLRS), Achromatopsia (ACHM) and X-linked Retinitis Pigmentosa (XLRP). To access a live webcast of this presentation, please visit A replay will be available for two weeks following the presentation.

About AGTC

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases in ophthalmology AGTC's lead product candidates, which are each in the preclinical stage, focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye, caused by mutations in single genes, that significantly affect visual function and currently lack effective medical treatments. AGTC has recently begun development of a product to treat Wet AMD using the companies experience in ophthalmology to expand into disease indications with larger markets.

Forward Looking Statements

Statements in this press release regarding Applied Genetics Technology Corporation that do not relate to historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, information concerning possible or assumed future results of operations, business strategies and operations, preclinical and clinical product development and regulatory progress, financing plans, potential growth opportunities, potential market opportunities and the effects of competition, and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Readers are cautioned that these forward-looking statements are subject to risks and uncertainties and are only predictions, and actual future events and results may differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to those risks and uncertainties that are discussed under "Risk Factors" in our registration statement on Form S-1 (File No. 333-193309), as amended, and our periodic and current reports filed with the SEC.  Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management's plans, estimates, assumptions and beliefs only as of the date of this release. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.



Contact Data